Art

J-GLOBAL ID：200902280838164875   Reference number：08A1180606

Metabolic Syndrome is Strongly Associated With Chronic Subclinical Inflammation in Patients Achieving Optimal Low-Density Lipoprotein-Cholesterol Levels in Secondary Prevention of Cardiovascular Disease

メタボリックシンドロームは心血管疾患の二次防止で最適低密度リポ蛋白質-コレステロール量を達成した患者で慢性亜臨床的炎症と関係する

Author (4)： MATSUO Yoshiki (Div. of Cardiology, Minami-Wakayama Medical Center) ,  HASHIZUME Toshikazu (Div. of Cardiology, Minami-Wakayama Medical Center) ,  SHIOJI Shusaku (Div. of Cardiology, Minami-Wakayama Medical Center) ,  AKASAKA Takashi (Dep. of Cardiovascular Medicine, Wakayama Medical Univ.)
Material： Circulation Journal  (Circ J)
Volume： 72  Issue： 12  Page： 2046-2050 (J-STAGE)  Publication year： 2008 
JST Material Number： F0908A  ISSN： 1346-9843  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： *慢性亜臨床的炎症 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=08A1180606&from=J-GLOBAL&jstjournalNo=F0908A") }}

JST classification (2)： Cardiovascular system diseases  (GJ03000C) ,  Metabolic diseases,nutritional diseases in general.  (GD05010J)

Substance index (1)： Cholesterol

Reference (23)：

• 1. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: Moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49: 2129-2138.
• 2. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: An analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005; 45: 1644-1648.
• 3. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006; 114: 281-288.
• 4. Matsuzawa Y. Metabolic syndrome-definition and diagnostic criteria in Japan. J Jpn Soc Int Med 2005; 94: 188-203.
• 5. IPAQ Research Committee: International physical activity questionnaire: Short last 7 days self-administered format (November 2005). Available from http://www.ipaq.ki.se (accessed 14 February, 2008).

Terms in the title (8)： メタボリックシンドローム ,  心血管疾患 ,  低密度リポ蛋白質 ,  コレステロール量 ,  患者 ,  慢性 ,  臨床 ,  炎症